Molecular Dynamics Simulation of Shock Response of CL-20 Co-crystals Containing Void Defects

To investigate the effect of void defects on the shock response of hexanitrohexaazaisowurtzitane(CL-20)co-crystals,shock responses of CL-20 co-crystals with energetic materials ligands trinitrotoluene(TNT),1,3-dinitrobenzene(DNB),solvents ligands dimethyl carbonate(DMC) and gamma-butyrolactone(GBL)with void were simulated,using molecular dynamics method and reactive force field.It is found that the CL-20 co-crystals with void defects will form hot spots when impacted,significantly affecting the decomposition of molecules around the void.The degree of molecular fragmentation is relatively low under the reflection velocity of 2 km/s,and the main reactions are the formation of dimer and the shedding of nitro groups.The existence of voids reduces the safety of CL-20 co-crystals,which induced the sensitivity of energetic co-crystals CL-20/TNT and CL-20/DNB to increase more significantly.Detonation has occurred under the reflection velocity of 4 km/s,energetic co-crystals are easier to polymerize than solvent co-crystals,and are not obviously affected by voids.The results show that the energy of the wave decreases after sweeping over the void,which reduces the chemical reaction frequency downstream of the void and affects the detonation performance,especially the solvent co-crystals.

Drug-Drug Interactions in Patients with Breast Cancer

The research paper investigates the intricate landscape of drug-drug interactions (DDIs) within the context of breast cancer treatment, with a particular focus on the elderly population and the use of complementary and alternative medicine (CAM). The study underscores the heightened susceptibility of elderly patients to DDIs due to the prevalence of polypharmacy and the widespread utilization of CAM among breast cancer patients. The potential ramifications of DDIs, encompassing adverse drug events and diminished treatment efficacy, are elucidated. The paper accentuates the imperative for healthcare providers to comprehensively understand both conventional and CAM therapies, enabling them to provide patients with informed guidance regarding safe and efficacious treatment options, culminating in enhanced patient outcomes.

Preparation of reduced sensitivity co-crystals of cyclic nitramines using spray flash evaporation

The present day weapon technology demands novel energetic materials that exhibit simultaneous high explosive yield and reduced sensitivity.This article demonstrates application of spray evaporation to prepare reduced sensitive co-crystals of high performance nitramine explosives like HMX and CL-20 with a relatively less insensitive explosive 1,1-diamino-2,2-dinitroethylene or FOX-7.Stronger intermolecurar hydrogen bonding in FOX-7 is responsible for limited solubility in nost of o rganic solvents.Large solubility differences of FOX-7 with HMX and CL-20 restricts ifs co-crystallization through classical methods that yields thermodynamically favorable product.Spray flash evaporation,a kinetic crystallization method,has been therefore adopted and could successfully produce CL-20/FOX-7(2:1) and HMX/FQX-7(4:1) co-crystals.The fine powdered materials obtained were characterized by SEM,powder XRD,Raman spectro scopy,DSC-TGA etc.Multipoint Raman spectra showed consistent occurrence of spectral features indicating stoichiometric co-existence of ingredients in the crystal lattices.DSC analysis showed absence of all thermally assisted solidsolid phase transformation in the co-crystals as they were observed in pristine materials.The thermal stability calculated in terms of activation barrier fordecomposition,revealed the CL-20/FOX-7 co-crystal to be interlediately stable on comparison to their constituents while,the HMX/FOX-7 co-crystal is more stable.Compared to pure HMX and CL-20,both the co-crystals have shown higher insensitivity to impact force,suggesting them to be suitable for future generation insensitive munitions.

Structure of Co-crystals Formation from Imidazolium and Aromatic Ligands

In this study, two new co-crystals based on rigid imidazolium ligand （2,2＇-（（1,1’- biphenyl）-4,4＇-diyl）bis（2H-imidazo[1,5-a]pyridine-4-ium） hexafluorophosphate （L）） and 4,4＇- bipyridine （Bpy） and benzene （Ben）, formulated as L（Bpy）0.5 （co-crystal 1） and L（Ben） （co-crystal 2）, were obtained. Crystal data for 1： Pī space group with α = 10.921（4）, b = 16.998（6）, c = 17.666（6） A, α = 95.720（7）, β = 104.272（7）, γ = 93.340（6）°, V = 3150.5（19） A^3 and Z = 2; and crystal data for 2： monoclinic C2/m space group with α = 25.90（2）, b = 9.631（9）, c = 6.371（6） A, β = 95.26（2）°, V = 1583（2） A3 and Z = 2. Co-crystal 1 was dependent on hydrogen bonds and π···π stacking, while only hydrogen bonds are present in 2. Two new co-crystals were characterized by IR, NMR spectra, thermogravimetric and ultraviolet absorption analyses.

One-step rapid preparation of CL-20/TNT co-crystal assembly and spheroidized coating based on droplet microfluidic technology

Energetic materials pose challenges in preparation and handling due to their contradictory properties of high-energy and low-sensitivity.The emergence of co-crystal explosives is a new opportunity to change this situation.If the co-crystal explosive is coated into spherical particles with uniform particle size distribution,this contradiction can be further reduced.Therefore,binder-coated hexanitrohexaazaisowurtzitane/2,4,6-trinitrotoluene(CL-20/TNT)co-crystal microspheres were prepared by droplet microfluidic technology in this work.The coating effects of different binder formulations of nitrocellulose(NC)and NC/fluorine rubber(F2604)on the co-crystal spheres were studied.The scanning electron microscopy(SEM)results showed that the use of droplet microfluidic technology with the above binders can provide co-crystal microspheres with regular spherical morphology,uniform particle size distribution and good dispersion.X-ray diffraction(XRD),fourier-transform infrared(FT-IR),differential scanning calorimetry(DSC)and thermo-gravimetric(TG)methods were employed to compare the properties of the co-crystal microspheres,raw material and pure co-crystal.The formation of CL-20/TNT co-crystal in the microspheres was confirmed,and the co-crystal microspheres exhibited better thermal stability than the raw material and pure co-crystal.In addition,the mechanical sensitivity and combustion performance of the co-crystal microspheres were further studied.The results showed that the co-crystal microspheres were more insensitive than CL-20 and pure co-crystal,and displayed excellent self-sustained combustion performance and theoretical detonation performance.This study provides a new method for the fast,simple and one-step preparation of CL-20/TNT co-crystal microspheres,with binder coating,uniform particle size distribution,and excellent performance level.

Theophyllineecitric acid co-crystals easily induced by DSCeFTIR microspectroscopy or different storage conditions

A simultaneous differential scanning calorimetryeFourier transform infrared(DSCeFTIR)microspectroscopy was used to quickly investigate the co-crystal formulation between anhydrous theophylline(TP)and anhydrous citric acid(CA)in a one-step procedure.The raw materials of TP andCA,aswell as the intactTPeCA co-crystal prepared by slow solvent evaporation were also respectively examined by this approach.The result indicates that the TPeCA cocrystal formulation was easily induced using this DSCeFTIR technique.The thermaldependent changes in three-dimensional FTIR spectral contour profiles were started from 165
C to induce the co-crystal formation of TPeCA,which was prior to the endothermic peak at 173
C found in the conventional DSC curve.Beyond 165
C,several new IR absorption peaks at 3515,3124,1730,1710,1677,1648,1552 and 1265 cm1 corresponding to unique IR spectral peaks of intact TPeCA co-crystal were observed.The DSCeFTIR microspectroscopic results also evidenced the dimeremonomer transition of CA,but there were no markedly changes for TP or intact TPeCA co-crystal before its fusion.This strongly implies that the DSCeFTIR technique giving spectroscopic and thermodynamic information could simultaneously induce and identify the TPeCA co-crystal formation and phase transition of samples.Different storage conditions affecting the stability of both physical mixture and ground mixture of TPeCA were also determined.The physicalmixture of TPeCA after storing at 55
C/75%RH condition for one day was fast transformed to TPeCA co-crystal,indicating that TPeCA co-crystal was easily induced under accelerated storage condition.While the co-crystal formed from TPeCA ground mixture was stable in both 25
C/75%RH and 55
C/75%RH conditions.

Spotted Hyena Optimizer Driven Deep Learning-Based Drug-Drug Interaction Prediction in Big Data Environment

Nowadays,smart healthcare and biomedical research have marked a substantial growth rate in terms of their presence in the literature,computational approaches,and discoveries,owing to which a massive quantity of experimental datasets was published and generated(Big Data)for describing and validating such novelties.Drug-drug interaction(DDI)significantly contributed to drug administration and development.It continues as the main obstacle in offering inexpensive and safe healthcare.It normally happens for patients with extensive medication,leading them to take many drugs simultaneously.DDI may cause side effects,either mild or severe health problems.This reduced victims’quality of life and increased hospital healthcare expenses by increasing their recovery time.Several efforts were made to formulate new methods for DDI prediction to overcome this issue.In this aspect,this study designs a new Spotted Hyena Optimizer Driven Deep Learning based Drug-Drug Interaction Prediction(SHODL-DDIP)model in a big data environment.In the presented SHODL-DDIP technique,the relativity and characteristics of the drugs can be identified from different sources for prediction.The input data is preprocessed at the primary level to improve its quality.Next,the salp swarm optimization algorithm(SSO)is used to select features.In this study,the deep belief network(DBN)model is exploited to predict the DDI accurately.The SHO algorithm is involved in improvising the DBN model’s predictive outcomes,showing the novelty of the work.The experimental result analysis of the SHODL-DDIP technique is tested using drug databases,and the results signified the improvements of the SHODLDDIP technique over other recent models in terms of different performance measures.

Pyrolysis of CL20-BTF Co-crystal via ReaxFF-lg Reactive Force Field Molecular Dynamics Simulations

To obtain detailed information on the potential energy, the evolution of species, the initial reaction paths, and thermal decomposition products, we conducted simulations on pyrolysis process of CL20/BTF co-crystal using the ReaxFF/lg reaction force field, with temperature set at 2000 K to 3000 K. With the analysis of evolution curves of potential energy based on exponential function, we obtain the overall characteristic time. Via a description of the total package reaction with classical Arrhenius law, we obtain the activation energy of CL20/BTF co-crystal： Ea=60.8 kcal/mol. Based on the initial path of CL20/BTF co-crystal thermal decomposition we studied, we conclude that N-NO2 bond of CL20 molecules breaks first, working as a dominant role in the initial stage of thermal decomposition under the condition of different temperatures, and that all CL20 molecules completely decompose before BTF molecular regardless of different temperatures. We also find that the main products of CL20/BTF co-crystal are NO2, NO, NO3, HNO, O2, N2, H2O, CO2, N2O, and HONO, etc., on which the temperature forms certain influence.

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell lymphomas.However,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased medicine.This evidence-based expert consensus was formulated using an evidence-based approach and the Delphi method.The Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,respectively.This consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special populations.This multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges

Tuberculosis(TB)remains a leading cause of death among infectious diseases,particularly in poor countries.Viral infections,multidrug-resistant and ex-tensively drug-resistant TB strains,as well as the coexistence of chronic illnesses such as diabetes mellitus(DM)greatly aggravate TB morbidity and mortality.DM[particularly type 2 DM(T2DM)]and TB have converged making their control even more challenging.Two contemporary global epidemics,TB-DM behaves like a syndemic,a synergistic confluence of two highly prevalent diseases.T2DM is a risk factor for developing more severe forms of multi-drug resistant-TB and TB recurrence after preventive treatment.Since a bidirectional relationship exists between TB and DM,it is necessary to concurrently treat both,and promote recommendations for the joint management of both diseases.There are also some drug-drug interactions resulting in adverse treatment outcomes in TB-DM patients including treatment failure,and reinfection.In addition,autophagy may play a role in these comorbidities.Therefore,the TB-DM comorbidities present several health challenges,requiring a focus on multidisciplinary collaboration and integrated strategies,to effectively deal with this double burden.To effectively manage the comorbidity,further screening in affected countries,more suitable drugs,and better treatment strategies are required.

Drug-drug cocrystals:Opportunities and challenges

Recently,drug-drug cocrystal attracts more and more attention.It offers a low risk,low-cost but high reward route to new and better medicines and could improve the physiochemical and biopharmaceutical properties of a medicine by addition of a suitable therapeutically effective component without any chemical modification.Having so many advantages,to date,the reported drug-drug cocrystals are rare.Here we review the drug-drug cocrystals that reported in last decade and shed light on the opportunities and challenges for the development of drug-drug cocrystals.

Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions

To quantify drug-drug-interactions (DDIs) encountered in patients prescribed hepatitis C virus (HCV) treatment, the interventions made, and the time spent in this process.METHODSAs standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral (DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir (LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir (OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTSSix hundred and sixty four patients (83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients.CONCLUSIONDDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care.

Non-merohedrally Twinned Crystal Structure of the Co-crystal Ethyl 6-(2-5-(Ethoxycarbonyl)-pyridin-2-yl-1,2-dihydroxyethyl)pyridine-3-carb-oxylateethyl 6-(2-5-(Ethoxycarbonyl)pyridin-2-yl-2-hydroxyacetyl)pyridine-3-carboxylate(0.69/0.31)

The two component molecules of the co-crystal 0.69（C18H2ON206）.0.31（C18H18N2O6） lie on a center-of-inversion that exists midway along the ethylene chain connecting the two aromatic rings. The two molecules are superimposed. The crystal is also a non-morohedral twin with a minor 37.7（2）% component. The refinement of this twinned and disordered crystal structure is detailed. Crystal data： C18H19.38N2O6, monoclinic, P21/c, a = 17.1687（8）, b = 5.4389（2）, c = 9.3261（4） A, b = 95.270（5）° and V= 867.18（6） A3 at -173 ℃.

Facial and bilateral lower extremity edema due to drug-drug interactions in a patient with hepatitis C virus infection and benign prostate hypertrophy: A case report

BACKGROUND New direct-acting antivirals(DAAs)-based anti-hepatitis C virus(HCV)therapies are highly effective in patients with HCV infection.However,safety data are lacking regarding HCV treatment with DAAs and drugs for comorbidities.CASE SUMMARY Herein,we reported a case of HCV-infection in a 46-year-old man with benign prostatic hypertrophy.The patient received sofosbuvir/velpatasvir as well as methadone maintenance therapy for drug abuse.The viral load became negative at week 1 post treatment.He developed facial and bilateral lower extremity edema 48 h after starting receiving tamsulosin.Edema disappeared 10 d after treatment with oral furosemide and spironolactone.CONCLUSION In conclusion,this is the first case of an acute edema in the course of treatment with new DAAs,methadone and tamsulosin.These agents are useful in clinical management of patients with HCV infection,particularly in men with benign prostatic hypertrophy.Clinicians should be aware of potential drug-drug interactions in this subset of patients.

Possibility of Drug-Drug Interaction in Prescription Dispensed by Community and Hospital Pharmacy

Objective: To analyze the use of all subsidized prescription drugs including their use of drug combination generally accepted as carrying a risk of severe interactions. Methodology: In a cross sectional study, we analyzed all prescriptions (n = 1014) involving two or more drugs dispensed to the population (age range 4-85 years) from all pharmacies, clinics and hospitals. Data were stratified by age and sex, and frequency of common interacting drugs. Potential drug interactions were classified according to clinical relevance as significance of severity (types A: major, B: moderate, and C: minor) and documented evidence (types 1, 2, 3, and 4). Result and Discussion: The growing use of pharmacological agents means that drug interactions are of increasing interest for public health. Monitoring of potential drug interactions may improve the quality of drug prescribing and dispensing, and it might form a basis for education focused on appropriate prescribing. To make the manifestation of adverse interaction subside, management strategies must be exercised if two interacting drugs have to be taken with each other, involving: adjusting the dose of the object drug;spacing dosing times to avoid the interaction. The pharmacist, along with the prescriber has a duty to ensure that patients are aware of the risk of side effects and a suitable course of action they should take. Conclusion: It is unrealistic to expect clinicians to memorize the thousands of drug-drug interactions and their clinical significance, especially considering the rate of introduction of novel drugs and the escalating appreciation of the importance of pharmacogenomics. Reliable regularly updated decision support systems and information technology are necessary to help avert dangerous drug combinations.

<i>In Vitro</i>and <i>in Vivo</i>(Mouse) Evaluation of Drug-Drug Interactions of Repaglinide with Anti-HIV Drugs

Repaglinide is type 2 short acting anti-diabetic drug which is primarily metabolized by CYP2C8 and CYP3A4 and is also a substrate of influx transporter OATP1B1. HIV drugs are potent inhibitors of CYP3A4 and OATP transporters. Several drug-drug interactions (DDIs) were noticed when protease inhibitors (PIs) coadministered with drugs metabolized by CYP3A4. The PIs are also potent mechanism based inhibitors, out which ritonavir is most potent. In the current study we evaluated in vitro (mouse and human liver microsomes) and in vivo DDIs of repaglinide with anti-HIV drugs. Out of the following tested drugs (Amprenavir, Indinavir, Nelfinavir, Ritonavir, Saquinavir, Delavirdine, Maraviroc, Efavirenz, Nevirapine and Ketoconazole) Amprenavir (APV), Ritonavir (RTV) and Ketoconazole (KTZ) showed inhibition of OH-repaglinide formation in human and mouse liver microsomes. The positive reversible inhibitions were further tested for irreversible inhibitions where we didn’t observe any irreversible inhibitions. In vitro inhibitions were further evaluated in the in vivo pharmacokinetics (mouse) where repaglinide pharmacokinetics was altered by RTV and KTZ. The DDIs in both studies were very strong;the dose of repaglinide is reduced to 20 fold. In conclusion, there could be possible DDIs when RTV dosed with repaglinide;we have also demonstrated that mouse could be useful preclinical tool when used in conjunction with in vitro screening models for DDIs.

Synthesis,Crystal Structure and Evaluations of Its Cytotoxicity,Anti-microbial and Anti-hydroxyl Radical Activities of a New Co-crystal Compound(C6H6Cl2N2O2S)·(Phen)·H2O

Co-crystal is a very potential kind of drug solid forms, and has a far-reaching influence on designing and preparing drugs. A new 1：1：1 co-crystal compound consisting of 4-amino-3,5-dichloro-benzenesulfonamide, 1,10-phenanthroline and water was synthesized, and its crystal structure was characterized by X-ray diffraction method. The compositions of the co-crystal are self-assembled into a three-dimensional network structure via intermolecular interactions including hydrogen bonds, π-π stacking, Cl？？？Cl interactions and van der Waals＇ forces. According to the evaluations of cytotoxicity assays, anti-microbial and anti-hydroxyl radicals, this co-crystal is a potential drug.

Short-Term Drug-Drug Interaction between Sildenafil and Bosentan under Long-Term Use in Patients with Pulmonary Arterial Hypertension

Sildenafil and bosentan are often co-administered for pulmonary arterial hypertension (PAH) treatment. The plasma concentration of sildenafil can be decreased by half if co-administered with bosentan. Many patients take these agents simultaneously in the morning and the evening. The aim of this study was to examine the pharmacokinetics of sildenafil which was interfered with bosentan administration to ascertain whether these agents should be given concomitantly or separately. A two-way crossover study was conducted in 6 PAH patients with combination therapy of sildenafil and bosentan. Participants underwent the sequence of treatment phases: phase S (sildenafil administered 3 h before bosen-tan);phase B (bosentan administered 3 h before sildenafil);and phase C (administered concomitantly). Blood samples were collected on the last day of each phase. There was no significant difference in maximum plasma concentration or area under the plasma concentration-time curve (AUC0-8) between phase C and phase S (95.5 ± 24.8 vs. 72.9 ± 40.9 (p = 0.07), 209.7 ± 81.8 vs. 180.2 ± 126.4 (p = 0.24), respectively) or between phases C and B (87.8 ± 42.0 vs. 99.6 ± 33.9 (p = 0.59), 197.2 ± 88.2 vs. 240.7 ± 121.8 (p = 0.19), respectively) (ng/mL, mean ± standard deviation). Large intra-and inter-individual variability in sildenafil concentration was noted. The timing of administration of sildenafil and bosentan does not significantly influence the plasma concentration of sildenafil. Physicians do not need to be overly concerned about the timing of administration of these drugs to maximize the sildenafil concentration.

Drug-Drug Interaction Studies of Levocetirizine with Atenolol

The objective of the study was to evaluate the drug-drug interaction studies of levoceterizine with atenolol. Calibration curve studies of working standard solutions of levocetirizine and atenolol （0.01-0.1 mmol） were scanned. Maxima appeared at 231 nm for levocetirizine and 224 nm for atenolol. The calibration curve obeyed Beer Lambert＇s Law. Lone availabilities of both the drugs were studied in pH 1, pH 4, pH 7.4 and pH 9 at 37℃ on B.P. （British Pharmacopoeia） dissolution apparatus. To study the drug-drug interaction of levocetirizine （5 mg tablet） and atenolol （100 mg tablet）, both the drugs were introduced to the dissolution apparatus in simulated gastric juice （pH 1）, pH 4, pH 7.4 and pH 9 at 37℃ at zero time and measured the absorbance maxima of both the drugs at the corresponding wavelength. Graphs were plotted for availability percentage （%） of drug versus time at each set of experiment. The availability percentage （%） of levocetirizine in the buffers of pH simulated to gastric pH 4, pH 7.4 and pH 9 in the presence of atenolol was 436.78%, 376.90%, 436.78% and 436.78%, respectively, but the availability of atenolol was increased up to 214.80%, 212.96%, 214.93% and 231.51% in simulated to gastric pH and in the buffers ofpH 4, pH 7.4 and pH 9, respectively. On the basis of these studies, it is concluded that levocetirizine forms a charge-complex with atenolol; therefore, co-administration of these drugs should be avoided.

Prevalence of Potential Drug-Drug Interactions in Hospitalized Surgical Patients

The objective of this study is to estimate the prevalence and describe the characteristics of pDDIs （potential drug-drug interactions） in medical prescriptions of hospitalized surgical patients. In this cross-sectional study, we analyzed 370 medical prescriptions from the surgery unit of a Mexican public teaching hospital. The identification and classification of potential drug-drug interactions were performed with the Micromedex 2.0 electronic drug information database. Results were analyzed with descriptive statistics and we estimated OR （odds ratio） to determine associated risk factors. From the study, it was found that the prevalence of potential drug-drug interactions was 45.9%. A total of 385 interactions were identified. Of these, 54.3% were classified as major and 60.5% as pharmacodynamic. Prescriptions for more than seven drugs （OR =7.33, CI （confidence interval） = 4.59-11.71） and advanced age 〉 60 years, （OR = 1.79, CI = 1.06-2.74） were positively associated with the presence of potential drug-drug interactions. We found a high prevalence of clinically relevant pDDIs in the surgery unit. In view of this outcome, the safety of drug combinations in hospitalized surgical patients should be evaluated during the prescription process in order to prevent adverse events.